^
Association details:
| Biomarker: | CCL19 overexpression |
|---|---|
| Cancer: | Follicular Lymphoma |
| Drug: | Rituxan (rituximab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Low CCL19 expression is associated with adverse clinical outcomes for follicular lymphoma patients treated with chemoimmunotherapy
Published date:
09/20/2021
Excerpt:
The whole 137 patients were all received rituximab in combination with chemotherapy as first-line treatment....Higher expression of CCL19 and RGL1 were significantly associated with longer OS (HR = 0.47, 95% CI [0.25–0.86], p = 0.014 for CCL19; HR = 0.34, 95% CI [0.13–0.90], p = 0.03 for RGL1)....CCL19 expression was associated with survival outcomes and might be a potential prognostic biomarker for FL treated with first-line chemoimmunotherapy.
Secondary therapy:
Chemotherapy
DOI:
10.1186/s12967-021-03078-9
